Public Employees Retirement System of Ohio Has $10.41 Million Stock Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Public Employees Retirement System of Ohio reduced its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 8.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 44,257 shares of the biopharmaceutical company's stock after selling 4,180 shares during the period. Public Employees Retirement System of Ohio's holdings in Alnylam Pharmaceuticals were worth $10,414,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the business. Focus Partners Advisor Solutions LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $203,000. Worldquant Millennium Advisors LLC lifted its position in shares of Alnylam Pharmaceuticals by 156.6% during the fourth quarter. Worldquant Millennium Advisors LLC now owns 150,191 shares of the biopharmaceutical company's stock worth $35,341,000 after purchasing an additional 91,671 shares in the last quarter. Zurich Insurance Group Ltd FI acquired a new position in shares of Alnylam Pharmaceuticals during the fourth quarter worth approximately $6,583,000. Vident Advisory LLC lifted its stake in shares of Alnylam Pharmaceuticals by 21.2% during the fourth quarter. Vident Advisory LLC now owns 1,327 shares of the biopharmaceutical company's stock valued at $312,000 after acquiring an additional 232 shares during the period. Finally, Soleus Capital Management L.P. lifted its position in Alnylam Pharmaceuticals by 29.3% during the 4th quarter. Soleus Capital Management L.P. now owns 76,800 shares of the biopharmaceutical company's stock valued at $18,072,000 after purchasing an additional 17,400 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

ALNY has been the topic of a number of analyst reports. Chardan Capital increased their price target on Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Wall Street Zen raised shares of Alnylam Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Stifel Nicolaus upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. Morgan Stanley reduced their price target on Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating for the company in a research report on Friday, April 11th. Finally, Canaccord Genuity Group increased their target price on shares of Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a "buy" rating in a report on Friday, March 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have given a buy rating to the company's stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY traded down $4.54 during midday trading on Wednesday, reaching $285.56. 905,329 shares of the stock were exchanged, compared to its average volume of 919,519. Alnylam Pharmaceuticals, Inc. has a twelve month low of $146.79 and a twelve month high of $304.39. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The company has a market cap of $37.23 billion, a P/E ratio of -131.59 and a beta of 0.17. The stock's 50 day simple moving average is $259.82 and its 200 day simple moving average is $254.53.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. During the same period last year, the business earned ($0.16) EPS. The firm's quarterly revenue was up 20.2% on a year-over-year basis. On average, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.